Program 2026

Thursday, May 7, 2026

09.45-10.00h Welcome and Introduction
Nuclear Medicine meets Neuro-Oncology. Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

10.00-11.00h Opening Keynote Lecture
Chairs: Michael Weller (Zurich), Timothy Cloughesy (Los Angeles)
Designing definitive clinical trials for novel therapies in brain tumors. Elizabeth Eisenhauer (Kingston)

11.00-12.00h Understanding PET RANO criteria
Chairs: Patrick Wen (Boston), Ben Ellingson (Los Angeles)
PET RANO in clinical trials: from conception to endpoint. Matthias Preusser (Vienna)
PET RANO in action: from guidelines to clinical cases. Nathalie Albert (Munich)
PET RANO response as primary endpoint? Panel discussion: Elizabeth Eisenhauer (Kingston), Andrew Scott (Melbourne), Matthias Preusser (Vienna), Nathalie Albert (Munich)

12.00-13.00h NMN Lunch

13.00-14.30h Clinical trials in the (hot)spotlight
Chairs: Roberta Ruda (Turin), Giuseppe Lombardi (Padua)
Theranostics in neuro-oncology: current clinical trial landscape. Erik Sulman (Durham)
The heat is on: clinical trials in focus.
The IPAX trial series. Nelleke Tolboom (Utrecht)
LUMEN-1 and MOMENTUM-1. Eng-Siew Koh (Sydney)

14.30-15.30h Proffered papers I: Hot data and burning questions
Chairs: Emilie Le Rhun (Zurich), Marcus Hacker (Vienna)
Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort – Antoine Verger (Nancy), Abstract No. 6
ReSPECT-LM: Pharmacokinetic and Pharmacodynamic assessment of Reyobiq in Leptomeningeal Metastases – Andrew Brenner (San Antonio), Abstract No. 47
PET-Based Dosimetry of Intra-Arterial Y-90 Neurovascular Radiotherapy in Recurrent Glioblastoma: First-in-Human Feasibility – Kazim Narsinh (San Francisco), Abstract No. 48
Evaluation of glioblastoma-brain assembloids as an advanced in vitro model for preclinical targeted radionuclide testing – Sarah Waelkens (Mol),  Abstract No. 37
Validation of PET RANO 1.0 criteria in a retrospective, single-center cohort of patients with IDH-mutant glioma – Maximilian Mair (Vienna), Abstract No. 34
Comparative response assessment using PET-RANO 1.0 and RANO 2.0 in vorasidenib-treated IDH-mutant gliomas: the VORAFET study – Diego Cecchin (Padova), Abstract No. 8
Interim FDG-PET in primary central nervous system lymphoma – Laura Rozenblum (Paris), Abstract No. 15
You can find the NMN 2026 abstract book here.

15.30-16.30h NMN Poster viewing with Coffee and Cake

16.30-17.30h Proffered papers II: Hot data and burning questions
Chairs: Norbert Galldiks (Cologne), Antoine Verger (Nancy)
[18F]FET PET enables histopathology-validated detection of non-contrast-enhancing glioblastoma – Roman Stürzl (Munich), Abstract No. 4
FET PET reveals considerable volumetric and spatial differences in tumor burden compared to conventional MRI in recurrent glioblastoma – Norbert Galldiks (Cologne), Abstract No. 13
Prognostic relevance of FET PET in patients with newly diagnosed glioblastoma – Jan-Michael Werner (Cologne), Abstract No. 42
Virtual postoperative 18F-FET-PET imaging as a surrogate imaging modality in recurrent glioblastoma assessment – Jocelyn Castille (Brussels), Abstract No. 44
Identification of prognostically relevant residual tumor burden in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET – Jens Blobner (Munich), Abstract No. 16
FET-PET in Glioblastoma (FIG) Study (TROG 18.06): Towards FET-PET-Guided Radiotherapy Target Volume Delineation in Glioblastoma – Eng-Siew Koh (Sydney), Abstract No. 38
Mapping of Myeloid Cells in the Tumor Microenvironment of Glioblastoma using Transport Vehicle Mediated TREM2 PET Imaging – Laura Bartos (Munich), Abstract No. 53
You can find the NMN 2026 abstract book here.

From 19.00h Networking Event

Friday, May 8, 2026

09.00-10.00 NMN Networking Coffee
Meet and greet:

  • David Collingridge (Lancet Oncology)
  • Ali Landmann (Lancet Medical Imaging and Theranostics)
  • Gelareh Zadeh (Neuro-Oncology Advances)
  • Matthias Preusser (Neuro-Oncology)
  • Maximilian Mair (EANO youngsters)

10.00-12.00h Innovations and controversies in theranostics
Chairs: Wim Oyen (Milan / Arnhem), tbd
#increasingthepower – the rise of alpha emitters. Wolfgang Wadsak (Vienna)
#theradosetics – the concept of precision dosing in theranostics. Christophe Deroose (Leuven)
#crossingthebarrier – the role of focused ultrasound and BBB transport. Roger Stupp (Chicago)
#trialsinprogress – the future of NMN theranostics
Targeting SSTR2 With [²¹²Pb]VMT-α-NET in meningioma patients: Design of the First in Human Phase I/IIa LEMONαDE Trial – Nathalie Albert (Munich), Abstract No. 55
Study protocol for PRECISE, a pilot clinical trial of transarterial radioembolisation in patients with recurrent glioblastoma – Gaia Ninatti (Melbourne), Abstract No. 26
Intra-arterial 4- [211At]astato-L-phenylalanine ([211At]APA) in [18F]fluoroethyl-L-tyrosine ([18F]FET) positive recurrent glioblastoma: study protocol for a phase 1 dose-escalation study (I-APACHE) – Anass El Ghalbouni (Utrecht), Abstract No. 5

12.00-13.00h NMN Lunch

13.00-14.30h NMN casting: theranostic targets for brain tumors – top or flop?
Chairs: Matthias Preusser (Vienna), Nathalie Albert (Munich)

Jury: Jolanta Kunikowska (Warsaw), Felix Sahm (Heidelberg), Francesco Cicone (Catanzaro)
EGFR Andrew Scott (Melbourne)
PSMA Sophie Veldhuijzen van Zanten (Rotterdam)
SSTR Christophe Deroose (Leuven)
FAP tbc
LAT1 Jan Werner (Cologne)
CA IX / XII Maximilian Mair (Vienna)
Discussion (all)

14.30-15.15h NMN Coffee

15.15-16.45h Amino acid PET for glioma imaging – toy or tool in clinical practice?
Chairs: Ian Law (Copenhagen), Giuseppe Minniti (Rome)
A global perspective on PET imaging in neuro-oncology. Andrew Scott (Melbourne)
PET for surgery planning is just a toy! Gelareh Zadeh (Rochester)
PET for surgery planning is an indispensable tool! Jörg-Christian Tonn (Munich)
    • Audience voting: toy or tool?
PET for radiotherapy planning is just a toy! Stephanie Combs (Munich)
PET for radiotherapy planning is an indispensable tool! Maximilian Niyazi (Tübingen)
    • Audience voting: toy or tool?
PET for follow-up is just a toy! Martin van den Bent (Rotterdam)
PET for follow-up is an indispensable tool! Anna Berghoff (Vienna)
    • Audience voting: toy or tool?

16.45-17.00h Conclusions and Farewell Drinks
Nathalie L. Albert (Munich), Matthias Preusser (Vienna)
Please note that Program and Speakers are subject to change.

The program for 2026 will be available for download soon.

Download Program 2026 here soon.